Bladder-builder welcomes windpipe

It's a big day in the consumer media, abuzz with the news that doctors linkurl:engineered a windpipe;http://www.the-scientist.com/article/daily/53878/ for a 30-year-old woman using her own stem cells, but at the offices of linkurl:Tengion,;http://www.the-scientist.com/article/daily/53878/ a Pennsylvania biotech currently building bladders using patient cells, it's just business as usual. This news "confirms what we know," said Gary Sender, chief financial officer at Tengion. "We know we are in

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
It's a big day in the consumer media, abuzz with the news that doctors linkurl:engineered a windpipe;http://www.the-scientist.com/article/daily/53878/ for a 30-year-old woman using her own stem cells, but at the offices of linkurl:Tengion,;http://www.the-scientist.com/article/daily/53878/ a Pennsylvania biotech currently building bladders using patient cells, it's just business as usual. This news "confirms what we know," said Gary Sender, chief financial officer at Tengion. "We know we are in an emerging field." Still, Sender added that any good news from the field of regenerative medicine is "very positive for Tengion." And for patients. "You and I as just citizens should be thrilled that there are advances in this technology," he said. "We think the more progress that's made in this field, the better." Just today (Nov 19), Tengion linkurl:announced;http://www.tengion.com/news/press/20081119.cfm that it completed a second closing of its Series C financing, receiving $21 million in additional equity. The company also recently wrapped up its phase 2 trial, consisting of 10 children with spina bifida, and plans to start a phase 3 sometime next year. (The company is not yet disclosing any data from the phase 2 trial.) The company is also moving forward with its plan to build bladders for patients with bladder cancer, a somewhat trickier procedure because of the risk that the patient's cancer cells could end up in the new organ. Sender said the company hopes to fill out an investigational new drug (IND) application early next year, and begin a clinical trial soon thereafter. When linkurl:I visited;http://www.the-scientist.com/article/daily/53878/ the company's main 2800 square-meter manufacturing facility last year, the labs were largely empty, but slowly filling with the state-of-the-art equipment needed to ramp up to a phase 3 trial. The facility is now set to go, Sender said. "We're ready to roll with the phase 3" trial.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo

Products

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA

sartorius-logo

Introducing the iQue 5 HTS Platform: Empowering Scientists  with Unbeatable Speed and Flexibility for High Throughput Screening by Cytometry

parse_logo

Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella

shiftbioscience

Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery